Pfizer's Talzenna To Compete With AZ's Lynparza In Breast Cancer After EU Okay
Executive Summary
European approval for its PARP inhibitor to treat BRCA-mutated breast cancer is clearly good news for the US giant but Talzenna will likely remain in Lynparza’s shadow in the near term.
You may also be interested in...
Pfizer’s Talzenna Wins English Funding After Price Discount, Three Years Behind Germany & France
Pfizer’s Talzenna is soon to be made available to National Health Service patients in England and Wales with HER2-negative advanced breast cancer with inherited BRCA mutations, after the company agreed to provide the PARP inhibitor at a larger discount than it originally offered.
England’s NICE Turns Down Pfizer’s Talzenna In HER2-Negative Breast Cancer
Pfizer’s Talzenna is not cost effective enough to be used on the National Health Service for patients with HER2-negative advanced breast cancer with inherited BRCA mutations, according to draft guidance from England’s health technology assessment body NICE.
EU 2019 Approvals: Novel Therapies Make Strong Showing
Bluebird bio’s gene therapy Zynteglo, Akcea’s antisense drug Waylivra and BioMarin’s enzyme substitution therapy Palynziq were among the novel innovative medicines that were approved in Europe in 2019.